Concepedia

Shu-Feng Zhou

SZ

Statistics

Publications

4

Citations

253

H-Index

4

Active since

2015

Affiliations

University of Science and Technology Beijing(Current)

Guiyang Medical University

University of South Florida

University of Utah

Ningxia Medical University

Shu-Feng Zhou is an author at University of Science and Technology Beijing specializing in cancer cell signaling, anticancer activity, and autophagy.

Publications per year

2015–2015

4

Publications

4

Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells

Shu-Feng Zhou, Shu-Ting Pan, Yiru Qin et al. · Drug Design Development and Therapy · 2015 · 115 citations · Full text

, , +17

Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells

Shu-Feng Zhou, Feng Wang, Hai Li et al. · Drug Design Development and Therapy · 2015 · 60 citations · Full text

, , +17

Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells

Shu-Feng Zhou, Chunxiu Yuan, Zhi-Wei Zhou et al. · Drug Design Development and Therapy · 2015 · 47 citations · Full text

, , +17

The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells

Shu-Feng Zhou, Jin-Ping Li, Yin-Xue Yang et al. · Drug Design Development and Therapy · 2015 · 31 citations · Full text

, , +17

1–4 of 4